Baxter’s War Games: Post-Heparin, Scientists Consider Supply Chain Threats
Executive Summary
Part of Baxter's response to its heparin contamination fiasco has been to bring its scientists together to imagine ways counterfeiters could infiltrate its supply chain and how they would be countered
You may also be interested in...
GMP Warnings Split Between Brand, Generic Firms; Congress Watches FDA
The number of prescription drug manufacturing warning letters from FDA remained roughly split between brands and generics during the last year, but brands dominated the citations in early 2008, in contrast to generics' dominance since mid-year, when the House Energy and Commerce Committee launched an investigation into the agency's handling of products produced by Ranbaxy
GMP Warnings Split Between Brand, Generic Firms; Congress Watches FDA
The number of prescription drug manufacturing warning letters from FDA remained roughly split between brands and generics during the last year, but brands dominated the citations in early 2008, in contrast to generics' dominance since mid-year, when the House Energy and Commerce Committee launched an investigation into the agency's handling of products produced by Ranbaxy
Dingell May Tighten Inspection Provisions In Safety Bill, After Ranbaxy Alert
House Energy and Commerce Committee Chairman John Dingell, D-Mich., is likely to strengthen FDA mandates proposed in his evolving global drug safety bill, in light of the new Import Alert for more than three dozen Ranbaxy products